MAP2K7 and colorectal carcinoma: Thus, similar to BRAF mutant CRC, the efficacy of BRAF inhibitors in melanoma was limited by the relief of feedback inhibition of RTK-RAS-RAF with consequent MEK-ERK pathway reactivation, an effect that could be blocked with combined BRAF/MEK inhibition.